RBC Capital Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $130
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has initiated coverage on Ligand Pharmaceuticals with an Outperform rating and a price target of $130.
July 30, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Ligand Pharmaceuticals with an Outperform rating and a price target of $130.
The initiation of coverage with an Outperform rating and a price target of $130 by RBC Capital is likely to positively impact Ligand Pharmaceuticals' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100